{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-024185","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.159267+00:00","generated_at":"2026-05-24T15:16:17.181291+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Collegium nominates Carlos Paya; founder Heffernan retires as Chairman, Santini named; appoints David Dieter as GC","bullets":["Dr. Carlos Paya nominated for election to Board at 2025 Annual Meeting; current venture partner at Abingworth/Carlyle.","Founder and Chairman Michael Heffernan will not stand for re-election and retire from Board at Annual Meeting.","Gino Santini named Chairman of the Board effective immediately after Annual Meeting; Heffernan to serve as Chairman until then.","Director Gwen Melincoff also retiring from Board at Annual Meeting; departures part of board refreshment, not due to disagreements.","David Dieter appointed EVP and General Counsel effective March 17, 2025; previously VP Legal at Horizon Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-024185","json":"https://secwatch.observer/filing/0001104659-25-024185.json","markdown":"https://secwatch.observer/filing/0001104659-25-024185.md","text":"https://secwatch.observer/filing/0001104659-25-024185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/tm259415d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:16:17.181291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"513ca5e21d","claim":"Carlos Paya was appointed as Director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"approved the nomination of Dr. Carlos Paya to stand for election","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"nominated"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9e19e0a311","claim":"Gwen Melincoff departed as Director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Gwen Melincoff also advised the Board that she will not stand for re-election at the Annual Meeting and will retire from the Board at that time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election and retire"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b2f1207de7","claim":"Michael Heffernan departed as Chairman of the Board at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Michael Heffernan, R.Ph., founder and current Chairman of the Board advised the Board that he will not stand for re-election at the Annual Meeting and will retire from the Board at that time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election and retire"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"f5fb1c15ec","claim":"Gino Santini changed role as Chairman of the Board at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"The Board has named Gino Santini, the Company’s lead independent director since 2018, as Chairman of the Board, effective immediately following the Company’s Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925024185/0001104659-25-024185-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"named Chairman of the Board"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}